Compounded vs Brand GLP-1: Legal Status, Quality, and the 503A/503B Landscape (2026)

Last updated: June 2026

Informational only. Not medical advice. This explains the legal and quality landscape for compounded GLP-1 medications. Rules change. Do not start, stop, or change any treatment based on this. Speak with a licensed clinician and pharmacist.

For two years, compounded semaglutide and tirzepatide were everywhere. That was legal only because the brand drugs were on the FDA's shortage list. Both are now off that list, and the legal ground that allowed mass compounding has mostly washed away. This guide explains what changed, how 503A pharmacies differ from 503B facilities, what the quality data shows, and the legitimate ways to get brand drugs cheaper.

What's the difference between compounded and brand-name GLP-1?

Brand-name GLP-1s are FDA-approved drugs. Compounded versions are not approved by the FDA at all. That is the core distinction, and it drives everything else.

A brand drug like Wegovy or Zepbound went through clinical trials. The FDA reviewed its safety, its dose, and its manufacturing. A compounded drug skips that review. It's made by a pharmacy or facility, not the original manufacturer.

Compounding is meant to fill real gaps. It lets a pharmacist make a drug for a patient who can't use the standard product. It was never meant to be a cheaper mass-market substitute for a drug that's widely available.

Feature	Brand-name (Wegovy, Ozempic, Zepbound, Mounjaro)	503A compounded	503B compounded
FDA-approved?	Yes	No	No
Made by	Original manufacturer	Local/telehealth pharmacy	Outsourcing facility
Made for	The general market	One named patient with a prescription	Bulk stock, can be office-use
Quality oversight	FDA pre-market review + cGMP	State board of pharmacy	FDA-registered, cGMP inspected
Active ingredient	The approved base molecule	Varies; salt forms have been used	Varies; salt forms have been used
Legal to make now?	Yes	Only narrow patient-specific cases	Largely blocked (see below)

The takeaway is simple. "Compounded semaglutide" is not a generic version of Wegovy. There are no FDA-approved generics for these drugs yet, because they're still under patent (FDA, 2025).

A generic only reaches the market after the FDA confirms it matches the brand and the patents expire. That hasn't happened here. So anything sold as a low-cost "semaglutide" that isn't the brand drug is, by definition, a compounded or unapproved product. The same logic applies to newer molecules like retatrutide sold as a research compound, which isn't approved or legally compoundable at all.

For more on this category, see our compounded GLP-1 peptides legal and safety status explainer.

Is compounding semaglutide and tirzepatide still legal in 2026?

For mass-market "copies," no. The legal basis ended when the drugs came off the shortage list. Federal law lets compounders make copies of an approved drug only when it's in shortage.

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025 (FDA, 2025). Once a drug is off the list, the shortage exception goes away.

The FDA set staggered wind-down deadlines so compounders could stop in an orderly way. They've all passed.

Drug	503A pharmacies stop	503B facilities stop
Tirzepatide	Feb 18, 2025	Mar 19, 2025
Semaglutide	Apr 22, 2025	May 22, 2025

Those dates come from the FDA's clarifying guidance (FDA, 2025). A trade group sued to block the deadlines. Courts denied the requests, and the deadlines held (Reuters, 2025).

In 2026 the agency went further. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, saying there's no clinical need to compound them from bulk (FDA, 2026). A public comment period runs through June 29, 2026.

That proposal matters because the bulks list is the back door. Even off the shortage list, an outsourcing facility could in theory compound a drug if its bulk ingredient sat on the 503B list. The 2026 proposal would slam that door for these three molecules.

In February 2026, FDA Commissioner Martin Makary said the agency intended to restrict GLP-1 ingredients being "mass-marketed" by compounders as alternatives to approved drugs (Pharmacy Times, 2026). That signals the direction is enforcement, not retreat.

So the door is closing, not just closed. Some patient-specific compounding may still be allowed in narrow cases, which is the next question. For the broader picture, see our peptide legality guide 2026.

What's the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy makes drugs one patient at a time. A 503B facility makes them in bulk under stricter federal rules. Both names come from sections of the Food, Drug, and Cosmetic Act.

A 503A pharmacy fills a prescription written for a specific, named person. It operates under state pharmacy boards. It doesn't have to follow the full federal manufacturing standard called cGMP.

A 503B outsourcing facility is different. It registers with the FDA, follows cGMP, and gets FDA inspections. It can make larger batches and supply clinics, not just individual patients.

Feature	503A pharmacy	503B outsourcing facility
Governing law	Section 503A of the FD&C Act	Section 503B of the FD&C Act
Primary oversight	State board of pharmacy	FDA registration + inspection
Manufacturing standard	Pharmacy-level (USP)	Full cGMP
Scale	Patient-specific	Bulk batches
Needs a patient name?	Yes, per prescription	Not always; can stock for office use
GLP-1 status in 2026	Narrow patient-specific cases only	Largely blocked; bulk exclusion proposed

Why does this matter for GLP-1 drugs? Because the rules for each path are now different. A 503A pharmacy can still compound for a documented, individual medical need that the brand product can't meet (Alston & Bird, 2025).

What counts as a real need? Think of a patient with a documented allergy to an inactive ingredient in the branded pen, or a clinically justified strength the manufacturer doesn't sell. Those are narrow, named-patient situations. They're not a business model for shipping the same formula to thousands of people.

A 503B facility faces a tougher bar. If the FDA's 2026 proposal is finalized, these molecules would be formally off the bulks list, blocking large-scale bulk compounding unless a shortage returns (FDA, 2026).

This is the heart of the 2025-2026 shift. The big telehealth volume ran mostly through compounders treating GLP-1s like a commodity. The remaining legal space is small and case-by-case, which is a very different business. For how this fits the wider regulatory picture, see our U.S. peptide therapy market report 2026.

How does the quality and safety of compounded GLP-1 compare?

Compounded GLP-1s carry real, documented quality and dosing risks that brand drugs don't. This isn't a hypothetical. The FDA and the manufacturers have published specifics.

Start with the active ingredient. Some compounders used salt forms, semaglutide sodium or semaglutide acetate, instead of the base molecule in approved drugs. The FDA says these salts are different active ingredients, and it isn't aware of a lawful basis for using them (FDA, 2025).

Then there's purity. Novo Nordisk testing of compounded samples reported impurities as high as 33% in one sample, and another product with about 19% less semaglutide than its label claimed (AJMC, 2025). High-impurity products raise concerns about immune reactions.

Dosing errors are the third problem. Many patients got multidose vials and had to measure their own doses. The FDA received reports of overdoses, some requiring hospitalization, from miscalculated doses (FDA, 2025).

Concern category	What the evidence shows	Source
Wrong active ingredient	Salt forms (sodium, acetate) differ from approved base; no lawful basis per FDA	FDA, 2025
Impurities	Up to ~33% impurities reported in tested samples; immunogenicity risk	AJMC, 2025
Underdosing/overdosing	One sample ~19% below labeled strength; self-measured doses caused overdoses	AJMC / FDA, 2025
Adverse event reports	600+ reports for compounded semaglutide as of mid-2025, likely undercounted	UIC Drug Info, 2025
Counterfeits	Fraudulent and counterfeit products entered the market	FDA, 2025

By July 2025, the FDA had logged more than 600 adverse event reports tied to compounded semaglutide, and the agency notes that's likely a fraction of the true total (UIC Drug Information Group, 2025).

There's also the counterfeit problem riding alongside the legal compounding market. The FDA has flagged fraudulent and counterfeit semaglutide products entering the supply chain, often sold online without a prescription (FDA, 2025). For a buyer, a sketchy "compounded" website and an outright counterfeit can look identical.

To be fair, not every compounded vial was bad. Quality varied a lot by source. But a patient usually can't tell a careful compounder from a sloppy one, and there's no FDA review backstopping either. That's the honest risk.

Does the "personalized/combination" compounding loophole hold up?

The FDA is skeptical, and it's actively challenging the "personalization" argument. Some telehealth firms kept selling compounded GLP-1s by calling them custom, often by adding vitamin B12 or tweaking the dose.

The pitch was that a "personalized" formula isn't a "copy," so the shortage rule doesn't apply. The FDA's 2026 guidance pushed back. Adding B12 doesn't automatically make a product non-copy, and matching a commercially available strength can still make it "essentially a copy" (National Law Review, 2025).

The agency also targeted the marketing. In September 2025, the FDA sent warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s (Drug Topics, 2025).

Then came the courts and the companies. Novo Nordisk ended its short-lived Hims & Hers partnership in June 2025, publicly accusing the firm of "illegal mass compounding" (Reuters, 2025).

Lilly has also warned that adding B12 to compounded GLP-1s poses safety risks rather than a benefit (eMarketer, 2025). The argument is that mixing in an extra ingredient adds a new variable without any trial data behind the combination.

The FDA's own clarification put a number on the copy question. If a "personalized" strength lands within about 10% of a commercially available dose, it can still count as essentially a copy (National Law Review, 2025). A prescriber also has to document why the specific combination serves that patient's clinical need.

The pattern is clear. Regulators and manufacturers treat "personalization" as a label, not a real clinical reason, unless a prescriber documents a genuine, patient-specific need. Bulk "personalized" programs don't meet that bar.

What are the legitimate ways to get GLP-1 cheaper than list price?

The brand makers now sell directly to cash patients at far lower prices than the old list price. This is the legal path that's appeared since the crackdown, and it changes the math for a lot of people.

Novo Nordisk launched NovoCare Pharmacy to ship Wegovy directly. The self-pay price dropped to $499/month, then to $349/month for all doses (Novo Nordisk, 2025).

Lilly did the same with LillyDirect and single-dose Zepbound vials. As of December 2025, the starting dose runs about $299/month, the 5 mg dose about $399, and other doses about $449 (Eli Lilly, 2025).

Path	What it is	Rough cash cost
NovoCare self-pay (Wegovy)	Direct from Novo Nordisk	~$349/mo, all doses
LillyDirect self-pay (Zepbound vials)	Direct from Lilly	~$299-$449/mo by dose
Insurance coverage	Plan covers part of cost	Varies; often a copay
Manufacturer savings cards	For commercially insured patients	Can lower copay sharply

There are also savings cards for people with commercial insurance, which can cut a copay sharply, and patient assistance programs for those who qualify. The mix of options is wider than it was at the height of the shortage.

Two things to keep in mind. These prices change, and they often exclude certain doses or come with conditions (CNBC, 2025). And insurance, when it covers these drugs, can still beat cash pay. The point isn't to push any product. It's that the legal options are now real and cheaper than they were.

It's worth noting the price gap that drove compounding has narrowed. When brand drugs cost $1,000-plus a month and were out of stock, a cheap compounded vial had obvious pull. With brand self-pay near $300-$350, the math has changed for many people, and so has the risk-benefit tradeoff.

What the evidence and law do and do not support

The law is clear that mass compounding of GLP-1 copies is over for now. The shortage exception is gone, the wind-down deadlines passed in 2025, and the FDA is moving to block bulk compounding outright.

The quality data supports caution. Salt-form ingredients, impurity findings, dosing errors, and 600-plus adverse event reports are documented, not invented.

What the evidence does not support is a blanket claim that every compounded vial harmed someone, or that compounding has no legitimate role. Narrow, patient-specific compounding still exists in law for documented needs. The "personalized" mass programs are what regulators reject.

It also doesn't support panic about the brand drugs themselves. Wegovy, Ozempic, Zepbound, and Mounjaro went through the FDA approval process and have published trial data behind them. The concern in this guide is specifically about unapproved compounded copies and the legal cliff they fell off in 2025.

If you're weighing your options, the practical question has shifted. Two years ago it was "where can I find this drug at all." Now it's "do I want an FDA-approved product at a self-pay price, or an unapproved compounded one with documented quality risks and a shaky legal footing." That's a real choice, and it belongs in a conversation with your clinician.

This is a fast-moving area. The 503B bulks proposal isn't final, and prices shift month to month. Treat any single number here as a snapshot, and confirm current rules and costs with a licensed clinician and pharmacist before acting.

Frequently Asked Questions

Is compounded semaglutide illegal in 2026?

Mass-market compounded copies no longer have a legal basis, because semaglutide came off the FDA shortage list in February 2025 and the wind-down deadlines have passed. Narrow, patient-specific compounding for a documented medical need may still be allowed in limited cases.

Why was compounded GLP-1 legal before but not now?

Federal law allows compounders to make copies of an approved drug while it's in shortage. Semaglutide and tirzepatide were on the shortage list, then removed in 2025. Once off the list, the shortage exception ended.

Is compounded semaglutide the same as Wegovy or Ozempic?

No. Brand drugs are FDA-approved and reviewed for safety, dose, and manufacturing. Compounded versions are not FDA-approved, and some used different salt forms that the FDA says are not the same active ingredient as the approved products.

What's the difference between 503A and 503B compounding?

A 503A pharmacy makes drugs for one named patient under state oversight. A 503B outsourcing facility makes bulk batches under FDA registration and cGMP manufacturing standards. The rules and limits for GLP-1 drugs differ between them.

Is brand-name GLP-1 cheaper now?

Yes, for cash-paying patients. Novo Nordisk's NovoCare offers Wegovy around $349/month, and Lilly's LillyDirect offers Zepbound vials starting around $299/month. Prices and eligibility change, so confirm the current terms directly.

Related Reading

• Compounded GLP-1 peptides: legal and safety status
• Compounded peptides vs research chemicals (2026)
• Peptide legality guide 2026

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.